This article considers the challenge of initiating insulin therapy in people with type 2 diabetes in a primary care setting. Professor Mike Kirby discusses the changing interface of primary and secondary care roles and the influence of guidelines, goals and targets. Issues of patient concern and selection of insulin regimen are also addressed.
Amos AF, McCarty DJ, Zimmet P.The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med1997 ;14(suppl 5):S1S85.
2.
Department of Health.National Service Framework for Diabetes: Delivery Strategy. London, UK: 2003.
3.
Department of Health.National Service Framework for Diabetes: Standards. London, UK: 2001.
4.
A Barnett AH , Capaldi B., Davies-Lyons M. et al. Expert opinion statement on the use of insulin therapy in patients with type 2 diabetes in primary care. Pract Diabetes Intern2003;20:97-102.
5.
Bailey CJ, Turner RCMetformin. N Engl J Med1996;334:574-9.
6.
Lebovitz HEAlpha-glucosidase inhibitors. Endocrinol Metab Clin North Am1997;26: 539-51.
7.
Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ2000;321:405-12.
8.
UK Prospective Diabetes Study (UKPDS) Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998;352:837-53.
9.
National Institute for Clinical Excellence.Inherited Clinical Guideline G: Management of Type 2 Diabetes - Management of Blood Glucose. London, UK, 2002.
10.
Barnett AH, Capaldi B., Farooqi A. et al. Treating to target in Type 2 Diabetes: from lifestyle change to insulin therapy. A consensus guideline. Modern Diabetes Management2003;4:2-5.
11.
UK Prospective Diabetes Study (UKPDS) Group.34. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet1998;352:854-65.
12.
Lepore M., Pampanelli S., Fanelli C. et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes2000;49:2142-8.
13.
Owens DR, Zinman B., Bolli GBInsulins today and beyond. Lancet2001;358:739-46.
14.
Rosenstock J., Schwartz SL, Clark CM, Jr. et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin . Diabetes Care2001;24:631-6.
15.
Yki-Järvinen H., Dressler A., Ziemen M.Less nocturnal hypoglycemia and better postdinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care2000;23:1130-6.
16.
Riddle MC, Rosenstock J., Gerich J.Treatment to target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care2003;26:3080-6.
17.
Fritsche A. , Schweitzer MA, Haring H.Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with Type 2 diabetes. Ann Intern Med2003;138:952-9.
18.
National Institute for Clinical Excellence.Technology Appraisal Guidance - No. 53. Guidance on the Use of Long-Acting Insulin Analogues for Treatment of Diabetes- Insulin Glargine . London, UK: 2002.
19.
Lindholm A. , Jacobsen LVClinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin Pharmacokinet2001 ;40:641-59.
20.
Feinglos MN , Thacker CH, English J., Bethel MA, Lane JDModification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes . Diabetes Care1997;20:1539-42.
